Contract research organizations occupy a unique position in the medical device ecosystem. While CROs don't typically hold FDA establishment registrations as manufacturers, the quality of services they provide directly impacts their clients' QMSR compliance, biocompatibility evaluations, and regulatory submissions. The QMSR's emphasis on process-based quality management, expanded FDA inspection authority, and integration of biocompatibility with design controls creates both ch

ISO 10993-1 sits at the center of how regulators expect you to think about biological safety. It is the international standard for biological evaluation of medical devices, and Part 1 provides the framework for structuring your entire biocompatibility strategy within a risk management process. The 2025 edition, represents the most significant change to biocompatibility evaluation in decades. The familiar endpoint matrix that guided testing decisions for over 30 years has been

Biocompatibility evaluation sits at the intersection of product safety, regulatory compliance, and quality system management. Under the QMSR , which incorporates ISO 13485:2016 by reference, biocompatibility must be fully integrated into your quality management system—not treated as a standalone testing exercise conducted outside your design and risk management processes. The publication of ISO 10993-1:2025 adds complexity and opportunity. The new standard's risk-based biol

On February 2, 2026, FDA retired the Quality System Inspection Technique (QSIT) and implemented a new inspection process described in Compliance Program 7382.850 . This change represents more than updated procedures—it reflects a fundamental shift in how FDA assesses medical device quality management systems under the QMSR. For manufacturers and CROs, understanding the new inspection approach and preparing your quality system for FDA review is essential for maintaining compli

As of February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has replaced 21 CFR Part 820 as the foundation for medical device quality systems in the United States. This transition incorporates ISO 13485:2016 by reference, harmonizing U.S. requirements with international quality management standards used by regulatory authorities worldwide. For medical device manufacturers, CROs, and regulatory affairs professionals, understanding what changed is essential fo

Bringing a medical device to the U.S. market means more than selecting a regulatory pathway. Your specific role shapes how you plan, generate, and defend biocompatibility and toxicological data within the FDA framework. Understanding Your Role in the Medical Device Approval Process Medical Device Manufacturers Manufacturers need a clear biocompatibility and toxicology strategy that starts at design input. Key challenges include: Translating intended use and contact duration

Extractables and leachables analysis sits at the core of modern biocompatibility assessment for medical devices. If your device uses polymers, adhesives, colorants, tubing, coatings, or packaging, you are dealing with potential chemical migrants that regulators expect you to understand and control. What Are Extractables and Leachables? Extractables are chemical constituents that move out of a device or material under aggressive laboratory conditions, such as exaggerated temp

Total medical compliance within the medical device industry refers to the complete and ongoing alignment of device development, testing, manufacturing, and post-market practices with regulatory and scientific standards that protect patient health and ensure market readiness. It encompasses far more than OSHA and HIPAA requirements. This is not about general workplace safety or patient data security. This is about biological safety and device functionality at the most granular

Material selection is one of the most critical decisions in medical device design, directly impacting both device performance and patient safety. For design engineers, understanding biocompatibility considerations during material selection can prevent costly redesigns, reduce testing iterations, and accelerate regulatory approval. This guide provides design engineers with practical biocompatibility considerations for selecting materials that meet both functional and biologica

Medical device biocompatibility evaluation is complex, and even experienced manufacturers can make costly mistakes that result in regulatory delays, additional testing requirements, and extended time-to-market. Understanding these common pitfalls can help you avoid them and streamline your path to approval. Based on extensive experience with regulatory submissions, here are the most frequent biocompatibility testing mistakes that cause approval delays—and how to prevent them.

Navigating the complex world of medical device biocompatibility can be overwhelming for manufacturers. With stringent regulatory...